Central Nervous System Tumor, CNS Tumor, Adult, CNS Tumor, Childhood, CNS Tumors, Low-grade Glioma, MAP Kinase Family Gene Mutation, Neuroblastoma, NF1, Optic Pathway Gliomas, Plexiform Neurofibroma, Primary Brain Tumor, Refractory Cancer, Solid Carcinoma, Solid Tumor, Solid Tumor, Adult
Conditions
Keywords
Refractory Cancer, Central nervous system tumor, CNS tumor, Plexiform Neurofibroma, Low-grade Glioma, Optic Pathway Gliomas, Neuroblastoma, Primary Brain Tumor, Solid Tumor, Solid Carcinoma, Avutometinib, Memorial Sloan Kettering Cancer Center, 23-129
Brief summary
The purpose of this study is to find out whether avutometinib is a safe treatment for advanced or recurrent solid tumor cancers in children and young adults. Researchers will look for the highest dose of avutometinib that is safe and cause few or mild side effects.
Interventions
DRUGAvutometinib
Participants will receive oral avutometinib once daily twice a week, three weeks on/ 1week off, for a period of 28 days per cycle
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
3 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
Patients must meet all of the following inclusion criteria to be eligible to enroll in this study: * Age ≥ 3 year and ≤ 30 years at the time of informed consent. \*Patients over 18 years of age will be treated at the adult RP2D. The accrual for patients \>18 and ≤ 30 years will be limited to no more than 5 patients overall and will not participate in the dose escalation. * All patients and/or their parents or legally authorized representatives must sign a written informed consent. Assent, when appropriate, will be obtained according to institutional guidelines. * Karnofsky ≥ 50% for patients \> 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age. * Participants must have one of the following: 1. Histologically confirmed diagnosis of a pediatric tumor including CNS tumors with activating MAP kinase pathway alterations including but not limited to BRAF/ARAF/CRAF fusions or mutations, KRAS/NRAS/HRAS alterations, PTPN11 or SOS1/2 mutations and/or loss of function alterations in NF1. This will be performed at the enrolling institution and central review is not required OR 2. Participants with a clinical or molecularly confirmed (germline alteration positive) diagnosis of NF1 with symptomatic inoperable plexiform neurofibromas and recurrent/progressive low-grade gliomas are eligible and may enroll without tissue/biopsy confirmation. OR 3. Patients with recurrent optic pathway gliomas are eligible if they have clinical progression (defined as new or worsening neurologic symptoms including visual dysfunction, as defined below): * Visual worsening, defined as worsening of visual acuity (VA) or visual fields (VF) documented within the past year (by examination or history); OR - Significant visual dysfunction (defined as VA worse than normal for age by 0.6 logMAR \[20/80, 6/24, or 2.5/10\] or more in one or both eyes). OR d) Participants with a confirmed diagnosis of neurofibromatosis 2 schwannomatosis (NF2-SWN) based on revised consensus 2021 criteria \[61\] with a target NF2-related tumor (vestibular schwannoma, non-vestibular schwannoma, meningioma) with documented radiographic progression defined as either: * ≥ 20% increase in volume of enhancing tumor * ≥ 2mm increase in greatest linear dimension of enhancing tumor Participants with diagnosis of NF2-SWN may enroll without tissue/biopsy confirmation. Genetic variants are classified as benign (B), likely benign (LB), likely pathogenic (LP), pathogenic (P), or variant of uncertain clinical significance (VUS) according to the standards and guidelines developed by the American College of Medical Genetics and Genomics, the Association for Molecular Pathology, and the College of American Pathologists \[62\]. Only patients with pathogenic and likely pathogenic variants in NF2 will be permitted to enroll \[61\]. Molecular testing requirements: Genetic alterations (SNVs or fusions) may be identified through local testing in a Clinical Laboratory Improvement Amendments (CLIA) laboratory in the US or equivalently accredited diagnostic lab outside the United States (US) (CLIA certified) by using molecular assays on any tumor samples (either at initial diagnosis or recurrence). Only the following test modalities are permitted: * Tissue-based or liquid biopsy NGS or quantitative polymerase chain reaction (qPCR) or RNA based fusion detection (ARCHER or other similar platform). The reports should be collected for any participants who have completed Next Generation Sequencing (NGS) at any point prior to or during study participation * Fluorescence in situ hybridization (FISH) * For subjects enrolled by a liquid biopsy test; blood samples will be required and should be sent prior to enrollment and used for retrospective confirmation in the Sponsor's designated central laboratory (MSKCC). * Patients must meet the following disease status criteria: * Solid tumor: Patients must have either measurable disease as measured by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (Version 1.1) or evaluable disease. * Neuroblastoma subjects are permitted to have evaluable disease only (e.g., bone disease only, evaluable by MIBG or PET). * Primary Brain Tumors: Patients with primary brain tumors are eligible and can either have measurable disease (defined as at least equal or greater than twice the slice thickness in two perpendicular diameters on MRI) OR evaluable disease (clear MRI evidence of disease that may not be measurable in two perpendicular diameters) OR diffuse leptomeningeal disease OR positive CSF cytology alone. * NF2 related schwannoma or meningioma: At least one volumetrically measurable and ≥1 cc NF2-SWN related VS or meningioma (histological confirmation not required), designated as target tumor. * Tumor is refractory or recurrent/progressive after standard therapy (at least one prior standard therapy appropriate for tumor type and stage of disease) unless available standard therapies are considered inadequate for the patient. Exception: NF1 patients with symptomatic and inoperable plexiform neurofibromas that are radiographically progressive or causing significant cosmetic disfigurement or causing significant morbidity are eligible regardless of prior MEK inhibitor exposure. NF2 patients with VS, non VS and meningioma are eligible prior to recurrence since no standard upfront treatment options exist. * Patients must have a body surface area (BSA) ≥ 0.8 m2 * Patients must be able to swallow intact capsules. * Patients may have received prior treatment with a RAF inhibitor (1st or 2nd generation) or MEK inhibitor but only as monotherapy (regardless of prior response to therapy). * Patients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy and meet minimum durations (shown below) from prior therapy. 1. Anti-cancer agents not known to be myelosuppressive: ≥ 7 days 2. Anti-cancer and cytotoxic agents known to be myelosuppressive: ≥ 14 days 3. Immunotherapies (including antibodies, interleukins, interferons, etc.): ≥ 21 days 4. Adoptive cellular therapies (including modified T cells, vaccines, etc.): ≥ 42 days 5. Autologous stem cell infusion (boost, no conditioning): ≥ 21 days 6. Autologous stem cell transplantation (with conditioning): ≥ 42 days 7. Allogeneic bone marrow transplantation: ≥ 84 days 8. Focal external beam radiation (e.g., limited sites of disease): ≥ 14 days 9. Substantial external beam radiation (e.g. whole lung or abdomen): ≥ 42 days 10. Radiopharmaceutical therapy (e.g., radiolabeled antibody or MIBG): ≥ 42 days * Adequate hepatic function (within 28 days prior to C1D1), defined as: 1. total bilirubin ≤ 1.5 × upper limit of normal (ULN) for the institution; patients with Gilbert syndrome may enroll if total bilirubin \< 3.0 mg/dL (51 μmole/L); 2. alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN (or \< 5x ULN in patients with liver metastases) 3. Albumin ≥ 3.0 g/dL (451 μmole/L). * Adequate renal function (within 28 days prior to C1D1) defined as a maximum serum creatinine for age and gender defined below. Patients that do not meet the criteria in Table 3 but have a 24 hour Creatinine Clearance or absolute GFR (radioisotope or iothalamate) ≥ 85ml/min are eligible. Age 1 month to \< 6 months: Maximum Serum Creatinine (mg/dL), Male: 0.4; Female: 0.4 Age 6 months to \< 1 year: Maximum Serum Creatinine (mg/dL), Male: 0.5; Female: 0.5 Age 1 to \< 2 years: Maximum Serum Creatinine (mg/dL), Male: 0.6; Female: 0.6 Age 2 to \< 6 years: Maximum Serum Creatinine (mg/dL), Male: 0.8; Female: 0.8 Age 6 to \< 10 years: Maximum Serum Creatinine (mg/dL), Male: 1; Female: 1 Age 10 to \< 13 years: Maximum Serum Creatinine (mg/dL), Male: 1.2; Female: 1.2 Age 13 to \< 16 years: Maximum Serum Creatinine (mg/dL), Male: 1.5; Female: 1.4 ≥ 16 years: Maximum Serum Creatinine (mg/dL), Male: 1.7; Female: 1.4 Table 3. The threshold creatinine values in this Table were derived from the Schwartz formula for estimating GFR Schwartz et al. J. Peds, 106:522, 1985) utilizing child length and stature data published by the CDC. * Adequate hematologic function (within 7 days prior to C1D1), defined as: 1. platelets ≥100,000/mm3; and 2. absolute neutrophil count (ANC) ≥ 1000/mm3. Note: Patients may not receive platelet transfusions nor hematopoietic growth factor support, including granulocyte-colony stimulating factor (e.g. filgrastim) and platelet stimulators (e.g. romiplostim) for at least 7 days prior to demonstrating adequate hematologic function.Patients with known malignant bone marrow infiltration are exempt from the above count requirements but should be discussed with sponsor. * Creatine phosphokinase (CPK) ≤ 2.5 x ULN. * Adequate recovery from toxicities related to prior treatments to at least Grade 1 by CTCAE v 5.0. Exceptions include alopecia and peripheral neuropathy grade ≤ 2. * Males or females of reproductive potential must agree to use an effective method of birth control, including a medically accepted barrier or contraceptive method (e.g., male or female condom) for the duration of the study. Abstinence is an acceptable method of birth control until one month after the last dose for female patients and 3 months after the last dose for male pts. Male patients should follow the same direction for sperm donation.
Exclusion criteria
Patients meeting any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of avutometinib | up to 12 months | The primary objective is to assess the safety of avutometinib in the pediatric population. CTCAE Version 5 will be utilized for toxicity evaluation. Adverse Events should be recorded from treatment start through 30 days after the last dose of study drug. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORSameer Farouk Sait, MD
Memorial Sloan Kettering Cancer Center
Outcome results
None listed